COMPETITIVE AND NONCOMPETITIVE NMDA ANTAGONISTS BLOCK THE DEVELOPMENTOF ANTINOCICEPTIVE TOLERANCE TO MORPHINE, BUT NOT TO SELECTIVE MU-OPIOID OR DELTA-OPIOID AGONISTS IN MICE
Ej. Bilsky et al., COMPETITIVE AND NONCOMPETITIVE NMDA ANTAGONISTS BLOCK THE DEVELOPMENTOF ANTINOCICEPTIVE TOLERANCE TO MORPHINE, BUT NOT TO SELECTIVE MU-OPIOID OR DELTA-OPIOID AGONISTS IN MICE, Pain, 68(2-3), 1996, pp. 229-237
N-Methyl-D-aspartate (NMDA) receptor antagonists have been shown to bl
ock the development of antinociceptive tolerance to morphine. Assessme
nt of the effects of NMDA antagonists on development of antinociceptiv
e tolerance to selective opioid mu (mu) and delta (delta) agonists, ho
wever, has not been reported. In these experiments, selective mu and d
elta receptor agonists, and morphine, were repeatedly administered to
mice either supraspinally (i.c.v.) or systemically (s.c.), alone or af
ter pretreatment with systemic NMDA antagonists. Antinociception was e
valuated using a warm-water tail-flick test. Repeated i.c,v. injection
s of mu agonists including morphine, fentanyl, [D-Ala(2), NMePhe(4), G
ly-ol]enkephalin (DAMGO) and Tyr-Pro-NMePhe-D-Pro-NH2 (PL017) or [D-Al
a(2), Glu(4)]deltorphin, a delta agonist, or s.c, injections of morphi
ne or fentanyl, produced antinociceptive tolerance as shown by a signi
ficant rightward displacement of the agonist dose-response curves comp
ared to controls. Single injections or repeated administration of MK80
1 (a non-competitive NMDA antagonist) or LY235959 (a competitive NMDA
antagonist) at the doses employed in this study did not produce behavi
oral toxicity, antinociception or alter the acute antinociceptive effe
cts of the tested opioid agonists. Consistent with previous reports, p
retreatment with MK801 or LY235959 (30 min prior to agonist administra
tion throughout the tolerance regimen) prevented the development of an
tinociceptive tolerance to i.c.v. or s.c. morphine. Neither NMDA antag
onist, however, affected the development of antinociceptive tolerance
to i.c.v. fentanyl, DAMGO, or [D-Ala(2), Glu(4)]deltorphin. Additional
ly, MK801 pretreatment did not affect the development of antinocicepti
ve tolerance to i.c.v. PL017 or to s.c. fentanyl. Further, MK801 pretr
eatment also did not affect the development of tolerance to the antino
ciception resulting from a cold-water swim-stress episode, previously
shown to be a delta-opioid mediated effect. These data lead to the sug
gestion that the mechanisms of tolerance to receptor selective mu and
delta opioids may be regulated differently from those associated with
morphine. Additionally, these findings emphasize that conclusions reac
hed with studies employing morphine cannot always be extended to 'opia
tes' in general.